Dietressa (canniboid receptor type 1) / Materia Medica - LARVOL DELTA

The use of drug based on technologically processed antibodies to endocannabinoid receptor type 1 in the treatment of obesity in adults: results of a multicenter double blind placebo controlled randomized clinical trial (PubMed, Ter Arkh) - "The monotherapy with Dietressa is safe, and it leads to at least 5 percent reduction in body weight during 24 weeks of therapy in patients with Class 1 obesity."

Clinical • Journal • Genetic Disorders • Obesity